MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Cardiovascular complications in Parkinsonism: insights from Luxembourg Parkinson’s Study

    S. Acharya, A. Lumley, Y. Devaux (Strassen, Luxembourg)

    Objective: Our study aimed at determining the frequency and risk of cardiovascular diseases (CVDs) in Parkinsonian patients in the Luxembourg Parkinson’s Study (LuxPARK). Background: The…
  • 2023 International Congress

    Long duration response to levodopa in advanced Parkinson disease

    P. Nieto, A. García, I. Martín, R. Ibañez, JP. Cabello, J. Vaamonde (Ciudad Real, Spain)

    Objective: In patients with advanced Parkinson disease, it is possible to obtain a response to duodopa, if the dose is adjusted appropriately, even taking periods…
  • 2023 International Congress

    A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson’s disease dementia.

    S. Pasternak, C. Silveira, K. Coleman, R. Garcia, J. Wells, M. Borrie, P. Macdonald, R. Bartha, M. Jenkins, S. Morrow, D. Mendonca, G. Zou, E. Finger, T. Rupar, R. Tirona, M. Jog (London, Canada)

    Objective: To evaluate the safety and tolerability of repurposing Ambroxol as a disease modifying treatment for Parkinson’s Disease Dementia (PDD). Background: Carrying a mutation in…
  • 2023 International Congress

    Does fatigue in Parkinson’s disease impact one’s physical function in daily live?

    B. Lindholm, E. Franzen (Malmö, Sweden)

    Objective: To investigate fatigue at baseline and 3.5 years later and its association with balance and gait over time. Background: In Parkinson’s disease (PD), fatigue…
  • 2023 International Congress

    Substantia Nigra blood-brain barrier opening in Parkinson´s disease: PET (18F-Choline) evidence of parenchymal penetration

    C. Gasca-Salas, P. Pineda-Pardo, M. Del álamo, T. Jiménez, C. Trompeta, L. García-Cañamaque, B. Fernández-Rodríguez, M. Matarazzo, I. Plaza Delasheras, E. Natera, R. Martínez-Fernández, S. Ruiz Deaguiar, J. Blesa, J. Obeso (Móstoles, Spain)

    Objective: To evaluate clinical safety, feasibility, and tissue penetration (by 18F-Choline PET) of MR-guided focused ultrasound (MRgFUS) blood-brain barrier opening (BBB-O) of the substantia nigra…
  • 2023 International Congress

    Tourette Syndrome with Functional Overlay: A Diagnosis Challenge and The Role of Electrophysiological Study

    O. Udomsirithamrong, R. Bhidayasiri, P. Panyakeaw (Bangkok, Thailand)

    Objective: To highlight the role of electrophysiological study (Ephy) as a useful diagnostic tool. Background: Tics with functional overlay are characterised by acute worsening of…
  • 2023 International Congress

    Does sleep disorder affect cognitive impairment in Parkinson’s disease?

    M. Miyashita, K. Hasegawa, M. Sagawa, A. Kumon (kanagawa, Japan)

    Objective: The aim of this study was clarified the relationship between cognitive dysfunction and sleep disorders in Parkinson's disease(PD). Background: In PD, cognitive decline increases…
  • 2023 International Congress

    Technological visuo-cognitive training in Parkinson’s disease: Preliminary findings from a pilot randomised controlled trial

    J. Das, G. Barry, R. Vitorio, R. Walker, C. Mcdonald, R. Morris, S. Stuart (Newcastle upom Tyne, United Kingdom)

    Objective: To determine the feasibility and preliminary efficacy of a home-based, technological visuo-cognitive training (TVT) intervention using a mobile application and exercise with stroboscopic glasses…
  • 2023 International Congress

    Investigation of usefulness of new MSA diagnostic criteria

    M. Tarisawa, M. Matsushima, A. Kudo, K. Sakushima, Y. Kanatani, N. Nishimoto, J. Sawada, T. Matsuoka, S. Hisahara, H. Uesugi, N. Minami, K. Sako, A. Takei, A. Tamakoshi, N. Sato, H. Sasaki, I. Yabe (Sapporo, Japan)

    Objective: We investigated the utility of the Movement Disorder Society Criteria (MDS criteria) including sensitivity and specificity. Background: Multiple system atrophy (MSA) is an adult-onset…
  • 2023 International Congress

    Learnings from inaugural year of foundation sponsored genetic counseling and testing program for Spinocerebellar Ataxia (SCA) types 1, 2, and 3

    K. Trace, N. Beck, L. Moore (Minneapolis, USA)

    Objective: To describe volume, genetic results, and participant perceptions of foundation sponsored genetic counseling and testing program for SCA 1, 2, and 3. Background: Molecular…
  • « Previous Page
  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley